Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKNUP3)

Drug Name
norfluoxetine Drug Info
Synonyms
Norfluoxetine; Desmethylfluoxetine; Norfluoxetin; 56161-73-0; 83891-03-6; 3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine; WIQRCHMSJFFONW-UHFFFAOYSA-N; gamma-(4-(Trifluoromethyl)phenoxy)benzenepropanamine; norfluoxetine hcl; 3-Phenyl-3-(4-trifluoromethyl-phenoxy)-propylamine; 3-phenyl-3-(4-(trifluoromethyl)phenoxy)propan-1-amine; Benzenepropanamine, gamma-(4-(trifluoromethyl)phenoxy)-; benzenepropanamine, gamma-[4-(trifluoromethyl)phenoxy]-; ( inverted exclamation markA)-
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
4541
CAS Number
CAS 83891-03-6
TTD Drug ID
DMKNUP3

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting 5-HT 2B receptor (HTR2B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [7]
Triflupromazine DMKFQJP Nausea MD90 Approved [8]
Minaprine DM0EP7M Depression 6A70-6A7Z Approved [9]
SPN-812 DMTV7XH Attention deficit hyperactivity disorder 6A05.Z Phase 4 [10]
Vabicaserin DM9GZW6 Psychotic disorder 6A20-6A25 Phase 2 [11]
PRX-08066 DMR7H2V Pulmonary arterial hypertension BB01.0 Phase 2 [12]
Pyrimidine derivative 29 DMVOYJ8 N. A. N. A. Patented [13]
Pyrimidine derivative 26 DM90WKN N. A. N. A. Patented [13]
Pyrimidine derivative 23 DM5MLQU N. A. N. A. Patented [13]
Pyrimidine derivative 25 DM51MFS N. A. N. A. Patented [13]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 2A receptor (HTR2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [7]
ZOTEPINE DMF3VXA Anxiety disorder 6B00-6B0Z Approved [14]
Iloperidone DM6AUFY Schizophrenia 6A20 Approved [15]
Flibanserin DM70DTN Depression 6A70-6A7Z Approved [16]
Lurasidone hydrochloride DMCVPXO Schizophrenia 6A20 Approved [17]
Aniracetam DMOIFW0 Cerebrovascular ischaemia 8B1Z Approved [18]
lumateperone tosylate DMQ8HOJ Schizophrenia 6A20 Approved [19]
Sarpogrelate DMGLP6S Diabetic complication 5A2Y Approved [20]
Pimavanserin DMR7IVC Parkinson disease 8A00.0 Approved [21]
Zicronapine DMP8ESD Schizophrenia 6A20 Phase 3 [22]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Voltage-gated potassium channel Kv3.1 (KCNC1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
[14C]TEA DM6SFYH Discovery agent N.A. Investigative [23]
Drug(s) Targeting 5-HT 2C receptor (HTR2C)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [7]
Lorcaserin DMG6OYJ Obesity 5B81 Approved [24]
Tramadol DMRQD04 Osteoarthritis FA00-FA05 Approved [25]
Mirtazapine DML53ZJ Depression 6A70-6A7Z Approved [4]
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [26]
Methysergide DM1EF73 Migraine 8A80 Approved [27]
Eltoprazine DMW6C81 Attention deficit hyperactivity disorder 6A05.Z Phase 3 [28]
M100907 DM7ZFBA Sleep-wake disorder 7A00-7B2Z Phase 3 [29]
SR46349B DM1ODMR Primary insomnia 7A00 Phase 3 [30]
Vabicaserin DM9GZW6 Psychotic disorder 6A20-6A25 Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By 5-hydroxytryptamine receptor 2C (HTR2C)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [4]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [4]
Fluoxetine DM3PD2C Bipolar depression Approved [4]
Fluphenazine DMIT8LX Psychotic disorder 6A20-6A25 Approved [31]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [32]
Nortriptyline DM4KDYJ Depression 6A70-6A7Z Approved [33]
Testosterone DM7HUNW Hot flushes GA30 Approved [34]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [35]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [36]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [37]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Gap junction alpha-1 protein (GJA1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [38]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [39]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [40]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [41]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [42]
Folic Acid DMEMBJC Colorectal carcinoma Approved [43]
Mifepristone DMGZQEF Cushing disease 5A70 Approved [44]
Letrozole DMH07Y3 Estrogen-receptor positive breast cancer Approved [38]
Carvedilol DMHTEAO Chronic heart failure BD1Z Approved [45]
Flutamide DMK0O7U Prostate cancer 2C82.0 Approved [46]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Potassium voltage-gated channel subfamily H member 2 (KCNH2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metoclopramide DMFA5MY Nausea MD90 Approved [47]
Quinidine DMLPICK N. A. N. A. Approved [48]
Verapamil DMA7PEW Angina pectoris BA40 Approved [49]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [50]
Clarithromycin DM4M1SG Acute maxillary sinusitis Approved [50]
Disopyramide DM5SYZP Long QT syndrome BC65.0 Approved [51]
Propranolol DM79NTF Angina pectoris BA40 Approved [52]
Amiodarone DMUTEX3 Tachyarrhythmias BC71 Approved [53]
Dofetilide DMPN1TW Sinus rhythm disorder BC9Y Approved [54]
Flecainide DMSQDLE Tachyarrhythmias BC71 Approved [50]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Choriogonadotropin subunit beta variant 2 (CGB2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [42]
Permethrin DMZ0Q1G Pediculus capitis infestation 1G00.0 Approved [55]
(+)-JQ1 DM1CZSJ Testicular cancer 2C80 Phase 1 [56]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [57]
Forskolin DM6ITNG Solid tumour/cancer 2A00-2F9Z Investigative [5]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 2A receptor (HTR2A) TTJQOD7 5HT2A_HUMAN Antagonist [2]
5-HT 2B receptor (HTR2B) TT0K1SC 5HT2B_HUMAN Antagonist [2]
5-HT 2C receptor (HTR2C) TTWJBZ5 5HT2C_HUMAN Antagonist [2]
Voltage-gated potassium channel Kv3.1 (KCNC1) TTVUWHQ KCNC1_HUMAN Inhibitor (gating inhibitor) [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
5-hydroxytryptamine receptor 2C (HTR2C) OT6H8DE0 5HT2C_HUMAN Protein Interaction/Cellular Processes [4]
Choriogonadotropin subunit beta variant 2 (CGB2) OTZJW4TH CGB2_HUMAN Gene/Protein Processing [5]
Gap junction alpha-1 protein (GJA1) OTT94MKL CXA1_HUMAN Gene/Protein Processing [5]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Gene/Protein Processing [6]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 208).
2 Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000 Dec 5;102(23):2836-41.
3 Effects of norfluoxetine, the major metabolite of fluoxetine, on the cloned neuronal potassium channel Kv3.1. Neuropharmacology. 2001 Sep;41(4):443-53.
4 Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulatio... Mol Pharmacol. 2008 Mar;73(3):748-57.
5 Effects of selective serotonin-reuptake inhibitors (SSRIs) on human villous trophoblasts syncytialization. Toxicol Appl Pharmacol. 2018 Jun 15;349:8-20. doi: 10.1016/j.taap.2018.04.018. Epub 2018 Apr 19.
6 Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br J Pharmacol. 2006 Nov;149(5):481-9. doi: 10.1038/sj.bjp.0706892. Epub 2006 Sep 11.
7 Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
8 Some properties of 5-hydroxytryptamine receptors in the hindquarters of the rat. Br J Pharmacol. 1979 Sep;67(1):79-85.
9 Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
10 New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300.
11 Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.
12 Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
13 Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
14 Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
15 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
16 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
17 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
18 Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
19 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
20 Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
21 Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
22 Clinical pipeline report, company report or official report of Lundbeck.
23 Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol. 1994 Jun;45(6):1227-34.
24 Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
25 The inhibitory effects of tramadol on 5-hydroxytryptamine type 2C receptors expressed in Xenopus oocytes. Anesth Analg. 2004 May;98(5):1401-6, table of contents.
26 Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005 Sep-Oct;60(5):441-60.
27 Spinal serotonin receptor activation modulates the exercise ventilatory response with increased dead space in goats. Respir Physiol Neurobiol. 2008 May 31;161(3):230-8.
28 Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
29 Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12.
30 SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 2002 Sep;27(3):430-41.
31 Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):11927-32. doi: 10.1073/pnas.0609752104. Epub 2007 Jul 2.
32 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
33 Downregulation of serotonin receptor subtypes by nortriptyline and adinazolam in major depressive disorder: neuroendocrine and platelet markers. Clin Neuropharmacol. 1993;16 Suppl 3:S19-31.
34 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
35 Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
36 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
37 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
38 Inhibition of estrogen receptor reduces connexin 43 expression in breast cancers. Toxicol Appl Pharmacol. 2018 Jan 1;338:182-190. doi: 10.1016/j.taap.2017.11.020. Epub 2017 Nov 24.
39 Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
40 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
41 Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4578-83.
42 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
43 Folate deficiency in normal human fibroblasts leads to altered expression of genes primarily linked to cell signaling, the cytoskeleton and extracellular matrix. J Nutr Biochem. 2007 Aug;18(8):541-52. doi: 10.1016/j.jnutbio.2006.11.002. Epub 2007 Feb 22.
44 Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
45 Reduced expression of endothelial connexins 43 and 37 in hypertensive rats is rectified after 7-day carvedilol treatment. Am J Hypertens. 2006 Feb;19(2):129-35. doi: 10.1016/j.amjhyper.2005.08.020.
46 Role of connexin 43 in cadmium-induced proliferation of human prostate epithelial cells. J Appl Toxicol. 2017 Aug;37(8):933-942. doi: 10.1002/jat.3441. Epub 2017 Feb 8.
47 Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005 Apr;74(1):31-6. doi: 10.1159/000083234. Epub 2005 Jan 7.
48 Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. doi: 10.1046/j.1540-8167.2005.04470.x.
49 Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol. 2004 Oct;2(5):497-506. doi: 10.1089/adt.2004.2.497.
50 Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.
51 Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol. 2008 Nov;155(6):957-66. doi: 10.1038/bjp.2008.325. Epub 2008 Aug 25.
52 Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol. 2006 Mar;147(6):642-52. doi: 10.1038/sj.bjp.0706508.
53 Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol. 1999 Mar;359(3):212-9. doi: 10.1007/pl00005344.
54 Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation. FEBS Lett. 2000 May 26;474(1):111-5. doi: 10.1016/s0014-5793(00)01586-6.
55 Exposure to Insecticides Modifies Gene Expression and DNA Methylation in Hematopoietic Tissues In Vitro. Int J Mol Sci. 2023 Mar 26;24(7):6259. doi: 10.3390/ijms24076259.
56 Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget. 2014 May 15;5(9):2355-71.
57 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.